shutterstock_1231106194_pajor_pawel

Pajor Pawel / Shutterstock.com

14 September 2023FeaturesBiotechnologySarah Speight

UK universities prove resilience during Horizon hiatus

Before news broke last week of the new Horizon funding deal for the UK, IP law firm Mathys & Squire reported that the UK’s 50 biggest universities filed 433 new patent applications in the period 2021-2022.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal

7 September 2023 The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

More on this story

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal

7 September 2023 The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.

More on this story

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal

7 September 2023 The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.

More features

Sarepta wins $115M in patent dispute over muscular dystrophy drug

CREATES Act unfairly tips the scales to generics

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

Trump’s return sparks calls for pro-patent agenda

Amgen faces pushback over bid to narrow patent scope